




**SCIENTIFIC ASSOCIATION OF THE
ONASSIS CARDIAC SURGERY CENTER
DEPARTMENT OF NONINVASIVE DIAGNOSTICS
CARDIOLOGY SECTION**

20th SYMPOSIUM on ECHOCARDIOLOGY



**October 4 - 5, 2019
Eugenides Foundation
(Ίδρυμα Ευγενίδου)
Athens-Greece**

Invited Faculty

ADAMOPOULOS S.	Athens, GR	LASKARI K.	Athens, GR
AGGELAKI M.	Athens, GR	LEONTIADIS E.	Athens, GR
AGELI K.	Athens, GR	LIVANIS E.	Athens, GR
APOSTOLOPOULOU R.	Athens, GR	MANGINAS A.	Athens, GR
ARMENIS I.	Athens, GR	MAKAVOS G.	Athens, GR
ATHANASSOPOULOS G.	Athens, GR	MAOUNIS TH.	Athens, GR
AVGEROPOULOU E.	Athens, GR	MARSONIS A.	Athens, GR
BARBETSEAS I.	Athens, GR	MYTAS D.	Athens, GR
BONIOS M.	Athens, GR	NIHOYANNOPOULOS P.	Athens, GR
BOUTSIKOU M.	Athens, GR	OLYMPIOS CH.	Athens, GR
CHANTANIS S.	Piraeus, GR	PAPADOPOULOS K.	Athens, GR
CHASIKIDIS C.	Athens, GR	PAPAMENTZELOPOULOS S.	Athens, GR
CHRISTOULAS G.	Athens, GR	PARTHENAKIS F.	Crete, GR
CHRYSOHERIS M.	Athens, GR	PATRIANAKOS A.	Crete, GR
COKKINOS DV.	Athens, GR	PERREAS C.	Athens, GR
DEMEROUTI E.	Athens, GR	PETROPOULOU E.	Athens, GR
DRITSAS A.	Athens, GR	PISIMISIS E.	Athens, GR
FRAGOULIS S.	Athens, GR	PLESSAS N.	Athens, GR
GIAMOZIS G.	Athens, GR	POLYDOROU A.	Athens, GR
GIANNAKOPOULOU V.	Athens, GR	POLYMEROS S.	Athens, GR
GKOUZIOUTA A.	Athens, GR	POULOS G.	Athens, GR
GOUDVENOS I.	Ioannina, GR	PSYCHARI S.	Athens, GR
HATZIGEORGIOU G.	Athens, GR	RALLIDIS L.	Athens, GR
IKONOMIDES I.	Athens, GR	SBAROUNI E.	Athens, GR
ILIODROMITIS E.	Athens, GR	STEFANIDIS A.	Piraeus, GR
KADOGLOU N.	Athens, GR	THEODOSIS-GEORGILAS A.	Athens, GR
KAFANTOGIAS A.	Athens, GR	THOMOPOULOU S.	Athens, GR
KALKANDI E.	Athens, GR	TRIKAS A.	Athens, GR
KALYVAS P.	Athens, GR	TSIAPRAS D.	Athens, GR
KANAKAKIS I.	Athens, GR	TSIGARIDAS N.	Athens, GR
KARABINOS E.	Athens, GR	TSOPOTOS I.	Athens, GR
KARAGIANNIS S.	Athens, GR	TSORLALIS I.	Kalamata, GR
KARATASAKIS G.	Athens, GR	TSOUKAS A.	Athens, GR
KARATZAS D.	Athens, GR	VARTELA V.	Athens, GR
KARYOFYLLIS P.	Athens, GR	VOUDRIS V.	Athens, GR
KATSAROS A.	Athens, GR	VOURNAS E.	Athens, GR
KOUTSOGIANNIS N.	Patra, GR	ZAHOS P.	Athens, GR
KLETTAS D.	Athens, GR		
KOURGIANIDIS G.	Athens, GR		
KOURIS N.	Athens, GR		
KRANIDIS A.	Athens, GR		
KYZOPOULOS S.	Athens, GR		

Organizing Committee

G. Athanassopoulos
G. Karatasakis
S. Kyrzopoulos
D. Tsiapras

Scientific Committee

G. Athanassopoulos	A. Chaidaroglou
G. Karatasakis	S. Fragoulis
S. Kyrzopoulos	F. Antoniou
D. Tsiapras	K. Ieromonachos
G. Kolovou	I. Armenis

GENERAL INFORMATION

Date

From Friday 4 of October 2019
to Saturday 5 of October 2019

Congress Venue

Eugenides Foundation
387, Syngrou Ave.
Kallithea
Athens-Greece

Organization

Noninvasive Cardiology Diagnostic
Department/Cardiology Section
Scientific Association of the Onassis
Cardiac Surgery Center

Language

The official congress language are
both English and Greek

Presentations by P/C

The auditorium will be equipped with
video projector for presentations via
P/C. The material must be delivered
at least one hour before the lecture
to the Presentation's Secretariat.

Registrations

FREE

Certification

After the end of the congress a
certificate of attendance will be given
providing a minimum attendance
time.

Site

<http://www.onasseio.gr>

Secretariat:

Phaedra Constantinidou, Eleni Binou
Onassis Cardiac Surgery Center
356, Sygrou Ave, 17674 Athens
Tel: 210-9493341, Fax: 210-9493336, email: akard@ocsc.gr

VALVE DISEASE 1

Chairpersons: *S. Chantanis, C. Perreas*

- | | |
|-------------|--|
| 09.00-09.20 | Asymptomatic severe aortic stenosis: When to intervene
<i>S. Kyrzopoulos</i> |
| 09.20-09.40 | Low flow aortic stenosis in heart failure. How to evaluate and proceed
<i>A. Stefanidis</i> |
| 09.40-10.00 | Moderate aortic stenosis with reduced ejection fraction: Can imaging guide therapy?
<i>N. Koutsogiannis</i> |
| 10.00-10.20 | Tricuspid regurgitation: when and how to intervene
<i>E. Leontiadis</i> |
| 10.20-10.30 | Discussants: <i>S. Polimeros, S. Thomopoulou, I. Tsorlalis</i> |

VALVE DISEASE 2

Chairpersons: *I. Barbetseas, A. Kranidis*

- | | |
|-------------|---|
| 10.30-10.50 | TAVI and mitral regurgitation
<i>E. Leontiadis</i> |
| 10.50-11.10 | Tricuspid regurgitation in patients undergoing mitral valve surgery
<i>G. Karatasakis</i> |
| 1.10-11.30 | What happens to mitral regurgitation in patients with AS undergoing surgery
<i>N. Kouris</i> |
| 11.30-11.50 | Timing of intervention in patients with AR. What happens to the LV
<i>E. Karabinos</i> |

11.50-12.00 **Discussants:** *P. Kalyvas, S. Papamentzelopoulos, I. Tsopotos*

12.00-12.30 Coffee Break

HEART FAILURE 1

Chairpersons: *S. Adamopoulos, K. Aggeli*

12.30-12.50 Clinical outcome in HF_{rEF}: Should we based on ejection fraction or on left ventricular global longitudinal strain?

S. Karagiannis

12.50-13.20 Prognostic role of cardiopulmonic exercise vs stress echo in heart failure

A. Dritsas

13.20-13.40 Management of heart failure in pediatric population

R. Apostolopoulou

13.40-14.00 Heart failure and endocarditis: Evidence from Euroendo survey 2019

I. Armenis

14.10-14.30 **Discussants:** *K. Laskari, V. Vartela, I. Vournas*

Light Lunch

HEART FAILURE 2

Chairpersons: *S. Iliodromitis, L. Rallidis*

15.30-15.50 Heart failure: Imaging inflammation or measuring markers in order to guide therapy?

K. Papadopoulos

15.50-16.10	Evaluation, treatment strategy and risk stratification of myocarditis <i>M. Boutsikou</i>
16.10-16.30	Infiltrative cardiomyopathy: How to diagnose and treat <i>G. Makavos</i>
16.30-16.50	Prognostic value of right ventricular dysfunction in heart failure <i>D. Mytas</i>
16.50-17.00	Discussants: <i>A. Gkouziouta, A. Kafantogias, E. Kalkandi</i>

HEART FAILURE 3

Chairpersons: *A. Marsonis, A. Trikas*

17.00-17.20	Prognosis of LBBB or pacing-induced cardiomyopathy <i>G. Kourgiannidis</i>
17.20-17.40	Diabetic cardiomyopathy: Risk stratification and therapy <i>E. Avgeropoulou</i>
17.40-18.00	Pericardial disease in heart failure <i>A. Theodosis-Georgilas</i>
18.00-18.20	Myocardial revascularisation in heart failure: When and how <i>I. Ikonomidis</i>
18.20-18.30	Discussants: <i>V. Giannakopoulou, D. Karatzas, N. Plessas</i>
18.30-19.00	Coffee Break

PULMONARY ARTERIAL HYPERTENSION

Chairpersons: A. Manginas, P. Nihoyannopoulos

19.00-19.20	When PHT is critical in valvular heart failure? <i>D. Tsiapras</i>
19.20-19.40	From pulmonary embolism to CTEPH: A unique pathway <i>P. Karyofyllis</i>
19.40-20.00	Secondary (type II) PHT: How to evaluate and treat? <i>E. Demerouti</i>
20.00-20.20	Dynamic changes of PHT: are they of clinical relevance? <i>G. Athanassopoulos</i>
20.20-20.30	Discussants: <i>G. Christoulas, G. Hatzigeorgiou, A. Polydorou</i>
20.30-20.35	Opening Remarks
20.35-21.15	RECEPTION

05.10.2019 Saturday

CHRONIC CORONARY ARTERY DISEASE

Chairpersons: I. Kanakakis, V. Voudris

- | | |
|--------------|--|
| 09.00-09.20 | MINOCA and Takotsubo syndrome: prevalence, diagnosis and risk stratification
E. Sbarouni |
| 09.20-09.40. | Chronic CAD risk stratification: Biomarkers vs imaging
N. Tsigaridas |
| 09.40-10.00 | The revascularized patient: How to risk stratify and when to intervene
N. Kadoglou |
| 10.00-10.20 | Epicardial adipose tissue as a risk marker for residual cardiovascular risk and arrhythmias
S.Psychari |
| 10.20-10.40 | Discussants: C.Chasikidis, G.Poulos, A.Tsoukas |

VALVE DISEASE 3

Chairpersons: I. Goudevenos, Ch. Olympios

- | | |
|-------------|---|
| 10.40-10.50 | Exercise-stress echocardiography in degenerative mitral regurgitation: When and why
D. Klettas |
| 10.50-11.10 | Patient selection in mitral valve repair
C. Perreas |
| 11.10-11.30 | Functional mitral regurgitation in severe heart failure. When and how to intervene (COAPT & MitraFR)
M. Chrysoheris |
| 11.30-11.50 | Mitral regurgitation. When too late to intervene
A. Patrianakos |

12.50-12.00 | **Discussants:** *S. Fragoulis, A.Katsaros, E. Petropoulou*

12.00-12.30 | Coffee Break

ATRIAL FIBRILLATION AND CARDIOEMBOLISM CLINICAL SCENARIA

Chairpersons: *G. Athanassopoulos, E. Livanis*

12.30-12.45 | AF and heart failure
M. Bonios

12.45-13.00 | AF and ACS
E. Pisimisis

13.00-13.15 | AF in Octogenarians
P. Zahos

13.15-13.30 | Lone AF
Th. Maounis

13.30-13.45 | AF in Renal failure
G. Giamouzis

13.45-14.00 | AF for secondary prevention of cardioembolism
M. Aggelaki

14.00-14.30 | **Keynote Lecture:**
Chairperson: *D. Cokkinos*
Diagnosis and risk stratification in cardiomyopathies
F. Parthenakis

**CLINICAL CASES COORDINATED BY THE
WORKING GROUP OF ECHOCARDIOGRAPHY
OF THE HELLENIC SOCIETY OF CARDIOLOGY**

**Chairpersons: *P. Nihoyannopoulos, K. Papadopoulos,
A. Stefanidis***

14.30-17.30	CASES
17.30	Closing Remarks



NOTES



Xarelto[®]

rivaroxaban

LGR MKT.10.2018.1097



Bayer

Κάτοχος της άδειας κυκλοφορίας:
Bayer AG, 51368 Leverkusen, Γερμανία
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ABEE,
Σωφού 18-20, 151 25 Μαρούσι,
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Κύπρο: Novagerr Ltd,
Tηλ.00357 22463858

Τμήμα Επιστημονικής Ενπληρώσεως
Τηλ: +30 210 6187742, Fax: +30 210 6187322
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπεριποίησης



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαρτύρων 95, 150 01 Τηρούς Αττικής,
Τηλ: 210 6193326 - 9, Fax: 210 6193300
ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σέβαστας 11, 115 28 Αθήνα,
Τηλ: 210 7489711, Fax: 210 7489731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ: 2310 459920 - 1, Fax: 2310 459269

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΥΡΙΑΗ ΚΑΡΤΑ»

Πριν τη συνταγογράφηση για κάθε ένδειξη συμβουλευθείτε την αντίστοιχη Περίληψη των Χαρακτηριστικών του Προϊόντος.